Skip to content
CIRI-IT
  • HOME_
  • Organization
    • The Origins
    • The Scientific Committee
    • The Center’s Objectives
    • Future Perspectives
  • Research
    • RSV ComNet Project
    • ID.DRIVE
  • Publications
  • News_
    • Nirsevimab: a new opportunity for RSV prevention in Newborns
    • Sexually transmitted diseases
    • Prevention and control of Influenza – 2024–2025 Season
    • The New Adjuvanted RSV Vaccine (RSVPreF3 OA) for Older Adults: Who Chose It First and Why
  • Contacts
    • Newsletter
  • Archive
    • Study on RSV epidemiology and impact: RESPIRA 50
    • EPSS Studies
  • Italiano
  • English
  • Toggle website search
Search this website
Menu Close
  • HOME_
  • Organization
    • The Origins
    • The Scientific Committee
    • The Center’s Objectives
    • Future Perspectives
  • Research
    • RSV ComNet Project
    • ID.DRIVE
  • Publications
  • News_
    • Nirsevimab: a new opportunity for RSV prevention in Newborns
    • Sexually transmitted diseases
    • Prevention and control of Influenza – 2024–2025 Season
    • The New Adjuvanted RSV Vaccine (RSVPreF3 OA) for Older Adults: Who Chose It First and Why
  • Contacts
    • Newsletter
  • Archive
    • Study on RSV epidemiology and impact: RESPIRA 50
    • EPSS Studies
  • Italiano
  • English
  • Toggle website search
Read more about the article RESPIRA-18 Project: Surveillance of Acute Respiratory Infections in Genoa (Italy)

RESPIRA-18 Project: Surveillance of Acute Respiratory Infections in Genoa (Italy)

Acute respiratory infections are significant causes of illness in the population during winter months,producing a significant impact, on health but also on the economy ed society.…

Continue ReadingRESPIRA-18 Project: Surveillance of Acute Respiratory Infections in Genoa (Italy)
Read more about the article The New Adjuvanted RSV Vaccine (RSVPreF3 OA) for Older Adults: Who Chose It First and Why
Shot of a doctor having a conversation with his patient in the clinic.

The New Adjuvanted RSV Vaccine (RSVPreF3 OA) for Older Adults: Who Chose It First and Why

Respiratory syncytial virus (RSV) is a name that many associate with acute respiratory infections in children. However, in recent years,…

Continue ReadingThe New Adjuvanted RSV Vaccine (RSVPreF3 OA) for Older Adults: Who Chose It First and Why
Read more about the article 2030 Agenda for Sustainable Development

2030 Agenda for Sustainable Development

Signed on September 25, 2015, by the governments of the 193 United Nations member states and approved by the UN…

Continue Reading2030 Agenda for Sustainable Development
Read more about the article Two RSV vaccines approved – 2023

Two RSV vaccines approved – 2023

In June 2023, the European Commission authorized a vaccine for active immunization to prevent lower respiratory tract disease (LRTD) caused…

Continue ReadingTwo RSV vaccines approved – 2023
Older Posts →

Search

CM_EN

  • HOME_
  • Organization
    • The Origins
    • The Scientific Committee
    • The Center’s Objectives
    • Future Perspectives
  • Research
    • RSV ComNet Project
    • ID.DRIVE
  • Publications
  • News_
    • Nirsevimab: a new opportunity for RSV prevention in Newborns
    • Sexually transmitted diseases
    • Prevention and control of Influenza – 2024–2025 Season
    • The New Adjuvanted RSV Vaccine (RSVPreF3 OA) for Older Adults: Who Chose It First and Why
  • Contacts
    • Newsletter
  • Archive
    • Study on RSV epidemiology and impact: RESPIRA 50
    • EPSS Studies
  • Italiano
  • English

Restricted Area

  • Accesso
  • DISSAL
  • UNIGE
© Copyright 2023 - CIRI-IT InterUniversity Research Center on Influenza

SPECIALE COVID-19

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In pulvinar erat ut venenatis maximus. Duis varius fermentum imperdiet. Morbi ipsum odio, ultricies non diam et, consectetur auctor lacus. Nunc a mi tellus. Nullam sit amet urna imperdiet, malesuada enim et, rutrum libero. Donec vel orci quis felis dapibus lobortis et at diam. Suspendisse at vehicula risus, maximus pretium dolor. Duis congue dolor nec ante dapibus, et venenatis libero finibus. Donec in mattis est. Morbi euismod, metus at lobortis rhoncus, lacus arcu malesuada lectus, sed pharetra magna diam ut purus. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Integer quis lorem vulputate, elementum lacus non, porta ipsum.